GoodRx Holdings (GDRX) Net Income towards Common Stockholders (2019 - 2026)

GoodRx Holdings (GDRX) has 8 years of Net Income towards Common Stockholders data on file, last reported at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 89.42% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $20.6 million (down 27.75% YoY), and the FY2025 full-year result was $30.4 million, up 85.72% from the prior year.
• Net Income towards Common Stockholders fell to $1.2 million in Q1 2026, from $5.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $58.8 million in Q2 2023 to a low of -$41.7 million in Q3 2022.
• A 5-year average of $370705.9 and a median of $1.2 million in 2026 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 4254.49% in 2023, while the deepest fall reached 1211.82% in 2023.
• Tracing GDRX's Net Income towards Common Stockholders over 5 years: stood at -$2.0 million in 2022, then tumbled by 1211.82% to -$25.9 million in 2023, then surged by 126.05% to $6.7 million in 2024, then dropped by 19.51% to $5.4 million in 2025, then plunged by 78.45% to $1.2 million in 2026.
• Business Quant data shows GDRX's Net Income towards Common Stockholders at $1.2 million in Q1 2026, $5.4 million in Q4 2025, and $1.1 million in Q3 2025.